Sixth BHD Symposium and First International Upstate Kidney Cancer Symposium: latest scientific and clinical discoveries

Gennady Bratslavsky; Mark R. Woodford; Michael Daneshvar; Mehdi Mollapour

doi:10.18632/oncotarget.7733

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meeting Reports:

Sixth BHD Symposium and First International Upstate Kidney Cancer Symposium: latest scientific and clinical discoveries

Gennady Bratslavsky _, Mark R. Woodford, Michael Daneshvar and Mehdi Mollapour

PDF | HTML | How to cite | Press Release | Video Interview

Oncotarget. 2016; 7:15292-15298. https://doi.org/10.18632/oncotarget.7733

Metrics: PDF 2253 views | HTML 19779 views | ?

Abstract

Gennady Bratslavsky1,2, Mark R. Woodford1,2,3, Michael Daneshvar1,2, Mehdi Mollapour1,2,3

1 Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA

2 Cancer Research Institute, SUNY Upstate Medical University, Syracuse, NY, USA

3 Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, USA

Correspondence to:

Mehdi Mollapour, email:

Gennady Bratslavsky, email:

Keywords: FLCN, Birt-Hogg-Dubé syndrome, renal cell carcinoma, clear cell renal cell carcinoma

Received: November 25, 2015 Accepted: January 29, 2016 Published: February 25, 2016

Abstract

The Sixth BHD Symposium and First International Upstate Kidney Cancer Symposium concluded in September 2015, in Syracuse, NY, USA. The program highlighted recent findings in a variety of areas, including drug development, therapeutics and surgical management of patients with BHD and multi-focal renal tumors, as well as multidisciplinary approaches for patients with localized, locally advanced and metastatic renal cell carcinoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7733

Publication Alerts

Post-Publication Promotion

Publication Discount

Meeting Reports:

Sixth BHD Symposium and First International Upstate Kidney Cancer Symposium: latest scientific and clinical discoveries

Abstract